TransCode Therapeutics Open Letter to Shareholders
13 mai 2024 08h30 HE
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders regarding a Reverse Stock Split
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
13 mai 2024 05h30 HE
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence
10 mai 2024 10h58 HE
|
King Faisal Specialist Hospital & Research Centre
KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
09 mai 2024 16h05 HE
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
09 mai 2024 08h50 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the...
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
09 mai 2024 08h00 HE
|
Bionano Genomics
Bionano announces significant advancements to its suite of computational tools for comprehensive cancer analysis.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09 mai 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
08 mai 2024 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
08 mai 2024 09h25 HE
|
Lixte Biotechnology Holdings, Inc.
Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024 (GLOBE...
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
08 mai 2024 09h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.